This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics

Register by 26 June to save £1000

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
3-5 November 2026
RAIAmsterdam, Netherlands

Dr. Sonja Merkas, PhD
Founder and CEO at Livinovea
Speaker

Profile

Sonja is the founder of Livinovea, a Switzerland-based consultancy and service provider supporting biotech, pharma, startups, and CDMOs across the drug development and manufacturing value chain. Livinovea integrates science and technology with market positioning and operational strategy — translating complexity into execution and measurable results. Clients engage us for:

1. Operational efficiency, cost reduction, operational excellence

2. Market positioning, business development, and growth strategy

3. CMC, technical transfer, due diligence, and hands-on troubleshooting across RNA, oligonucleotides, small molecules, and peptides

Outside Perspective. Inside Execution. Measurable Results.

Sonja brings over 25 years of experience in the life science industry and consulting, with a focus on oligonucleotide and small molecule therapeutics since 2003 — including 10 years at Novartis leading the oligonucleotide development portfolio. She holds a PhD in Chemistry and a Lean Six Sigma Black Belt.

Agenda Sessions

  • CMC Decisions That Influence Cost of Goods (COGs) in Oligo Scale-up: Levers for Scientific and Commercial Impact

    09:00
  • Chairwoman's Remarks: Innovations in Oligonucleotide CMC

    08:00